TransMedics Group Inc. (TMDX) Stock Falls on Q1 2026 Earnings

TransMedics Group Inc. (TMDX) delivered first-quarter 2026 results showing revenue growth alongside weaker profitability and a sizable market reaction.

Revenue: $173.9 million, up 21.2% year-over-year.

Gross profit: $101.2 million, up 14.7% year-over-year.

Cost of sales: $72.8 million, up 31.6% year-over-year.

Operating profit: $13.3 million, down 51.6% year-over-year.

Net income attributable to common shareholders: $7.3 million; diluted earnings per share: $0.20, down 71.5% and 71.4% year-over-year, respectively.

Cash from operating activities: $34.5 million, down 1308.9% year-over-year.

Purchases of property, plant and equipment: $15.5 million, down 42.6% year-over-year.

Cash and cash equivalents: $461.7 million, up 48.9% year-over-year.

Total liabilities: $940.8 million, up 64.7% year-over-year.

Consensus estimates versus results: revenue estimate $176.1 million (actual below estimate) and EPS estimate $0.63 (actual below estimate).

Market reaction: stock down 14.15% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

TransMedics Group Inc. Insider Trading Activity

TransMedics Group Inc. insiders have traded $TMDX stock on the open market 11 times in the past 6 months. Of those trades, 1 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $TMDX stock by insiders over the last 6 months:

GERARDO HERNANDEZ (Chief Financial Officer) has made 0 purchases and 4 sales selling 8,531 shares for an estimated $1,245,831.
DAVID WEILL has made 0 purchases and 2 sales selling 8,571 shares for an estimated $1,217,494.
WALEED H HASSANEIN (President & CEO) purchased 8,775 shares for an estimated $1,000,350
ANIL P. RANGANATH (See remarks) has made 0 purchases and 2 sales selling 3,864 shares for an estimated $555,859.
NICHOLAS CORCORAN (See remarks) sold 2,966 shares for an estimated $412,629
STEPHANIE LOVELL sold 1,193 shares for an estimated $178,496

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive TMDX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

TransMedics Group Inc. Hedge Fund Activity

We have seen 221 institutional investors add shares of TransMedics Group Inc. stock to their portfolio, and 204 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,281,090 shares (-76.7%) from their portfolio in Q4 2025, for an estimated $399,144,598
MACQUARIE GROUP LTD removed 906,268 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $110,247,502
LIONTRUST INVESTMENT PARTNERS LLP removed 523,748 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $63,713,944
MARSHALL WACE, LLP removed 351,208 shares (-64.8%) from their portfolio in Q4 2025, for an estimated $42,724,453
INVESCO LTD. added 298,770 shares (+77.4%) to their portfolio in Q4 2025, for an estimated $36,345,370
WELLINGTON MANAGEMENT GROUP LLP added 217,180 shares (+100.5%) to their portfolio in Q4 2025, for an estimated $26,419,947
TWO SIGMA INVESTMENTS, LP removed 199,425 shares (-31.4%) from their portfolio in Q4 2025, for an estimated $24,260,051

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

TransMedics Group Inc. Analyst Ratings

Wall Street analysts have issued reports on $TMDX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 12/08/2025

To track analyst ratings and price targets for TransMedics Group Inc., check out Quiver Quantitative's $TMDX forecast page.

TransMedics Group Inc. Price Targets

Multiple analysts have issued price targets for $TMDX recently. We have seen 8 analysts offer price targets for $TMDX in the last 6 months, with a median target of $148.5.

Here are some recent targets:

Daniel Markowitz from Evercore ISI Group set a target price of $118.0 on 04/06/2026
Thomas Stephan from Stifel set a target price of $130.0 on 03/09/2026
Mike Matson from Needham set a target price of $174.0 on 02/25/2026
Matt O'Brien from Piper Sandler set a target price of $160.0 on 02/25/2026
Allen Gong from JP Morgan set a target price of $149.0 on 02/25/2026
Suraj Kalia from Oppenheimer set a target price of $175.0 on 02/25/2026
William Plovanic from Canaccord Genuity set a target price of $148.0 on 12/17/2025